| Excerpt | Reference |
|---|
| "IgA nephropathy is not a benign condition in the UK and patients with impaired renal function and/or those with a reduced serum albumin are significantly more likely to progress to end-stage renal failure within 10 years." | ( Braumholtz, DA; Brown, JS; Davison, AM; Johnston, PA, 1992) |
| "Erythema nodosum and IgA nephropathy are nosologic entities with an immunologic background." | ( Dux, S; Grosskopf, I; Rosenfeld, JB, 1988) |
| "IgA nephropathy is induced by the IgA-immune complex (IC)." | ( Chen, A; Chou, WY; Ding, SL; Ho, YS; Shaio, MF; Sheu, LF; Shieh, SD; Song, YB, 1994) |
| "IgA nephropathy (Berger's disease) is one of the commonest forms of glomerular disease, not rarely progressing to renal failure." | ( Baicchi, U; Barsotti, G; Bernini, W; Cupisti, A; de Caterina, R; Giannessi, D; Sagripanti, A, 1993) |
| "IgA nephropathy is one of the most common forms of glomerular disease." | ( Brandt, R; Chan, JC; Chan, W; Futterweit, S; Ma, C; Maesaka, J; Trachtman, H; Valderrama, E; Wakely, P, 1996) |
| "IgA nephropathy (Berger's disease) is thought to be the most common primary glomerulonephritis in the world." | ( Chan, JC; Langman, CB; Lin, CY; Scheinman, JI; Trachtman, H, 1997) |
| "IgA nephropathy is the most common glomerulonephritis all over the world and a considerable proportion of the patients reaches end-stage renal failure." | ( Chábová, V; Jirsa, M; Merta, M; Rychlík, I; Stejskal, J; Stejskalová, A; Tesar, V; Zabka, J, 1996) |
| "IgA nephropathy is progressive in most cases and has no established therapy." | ( Altieri, P; Andrulli, S; Bolasco, PG; Fogazzi, GB; Locatelli, F; Ponticelli, C; Pozzi, C, 1999) |
| "The hallmark of Berger's disease is the mesangial and/or mesangioparietal deposition of IgA as the predominant or sole immunoglobulin." | ( Ferrario, F; Napodano, P; Rastaldi, MP, 1999) |
| "Idiopathic IgA nephropathy is widely regarded as a slowly progressive disease that not infrequently results in end-stage renal failure." | ( Chambers, ME; Hall, FW; McDonald, BR; Rabetoy, GM, 1999) |
| "IgA nephropathy is the most common glomerular disease worldwide." | ( Donadio, JV, 2000) |
| "IgA nephropathy is associated with a wide spectrum of possible lesions." | ( Berutti, S; Cesano, G; Ferro, M; Piccoli, G; Roccatello, D; Rossi, D; Salomone, M; Sena, LM, 2000) |
| "Hyperuricemia in IgA nephropathy is derived from both glomerular and tubulointerstitial damage, and correlated with hypertension." | ( Gomi, H; Hikita, M; Hosoya, T; Ichida, K; Ohno, I; Okabe, H, 2001) |
| "IgA nephropathy is the most common form of idiopathic glomerulonephritis." | ( Fluck, RJ; Lambie, SH; McIntyre, CW, 2001) |
| "IgA nephropathy is an immune-complex glomerulopathy that can result in capillary or extra-capillary proliferation." | ( Hennigar, R; Lohavichan, V; Tumlin, JA, 2003) |
| "IgA nephropathy is the world's most common primary glomerulonephropathy." | ( Alon, US; Chan, JC; Flynn, JT; Lande, MB; Mahan, JD; Norkus, EP; Scheinman, J; Trachtman, H; Weiss, RA, 2003) |
| "IgA nephropathy is quite a common disease with an annual incidence around 25 per 10(6) inhabitants." | ( Alamartine, E, 2003) |
| "IgA nephropathy is one of the most common causes of glomerulonephritis in the world and is characterized histologically by the deposition of polymeric forms of IgA within the mesangium and in some cases along the glomerular capillary wall." | ( Hennigar, RA; Tumlin, JA, 2004) |
| "IgA nephropathy is the most common primary glomerulopathy." | ( Blau, A; Kopolovic, J; Koukoui, L; Livneh, A; Pras, M, 2004) |
| "The pathogenesis of IgA nephropathy is still unknown, and treatment remains controversial." | ( Agras, PI; Baskin, E; Bilezikci, B; Cengiz, N; Saatci, U, 2005) |
| "IgA nephropathy is the primary renal disease with the greatest impact on services." | ( Ballardie, FW; Cowley, RD, 2008) |
| "IgA nephropathy is the most common type of the glomerulonephritis all over the world." | ( Jabur, WL, 2009) |
| "IgA nephropathy is one of the most common glomerular diseases in children." | ( Chen, SM; Jiang, XY; Mo, Y; Sun, LZ; Wu, W; Yue, ZH, 2009) |
| "Although IgA nephropathy is a common cause of hematuria, it is an extremely rare cause of pulmonary renal syndrome, causing high mortality, and has mostly been reported in adult patients." | ( Browne, L; Dishop, MK; Eldin, K; Elenberg, E; Elidemir, O; Srivaths, P, 2010) |
| "IgA nephropathy is the most common form of glomerulonephritis, and many patients with this disorder progress to renal failure." | ( Chen, J; Chen, S; Wang, L; Zhang, Y; Zhuang, Y, 2010) |
| "IgA nephropathy is the most common non-lupus glomerulopathy." | ( Hudaverdı, O; Keser, G; Kobak, S; Oksel, F, 2011) |
| "IgA nephropathy is a disease where the pathogenesis is still poorly understood." | ( Chan, CM; Fook-Chong, S; Lau, YK; Puong, KY; Tan, HB; Wong, KS; Woo, KT; Zhao, Y, 2010) |
| "IgA nephropathy is common in young people and one third of it results in end stage renal disease." | ( Ahmed, TA; Bashir, MM; Tipu, HN, 2011) |
| "IgA nephropathy is the most common primary glomerulonephritis worldwide." | ( Degrell, P; Késoi, I; Kovács, T; Nagy, J; Sági, B; Vas, T; Wittmann, I, 2011) |
| "IgA nephropathy is the most common cause of primary glomerulonephritis." | ( Kalantari, S; Mahmudieh, L; Nafar, M; Rezaei-Tavirani, M; Rutishauser, D; Samavat, S; Zubarev, RA, 2013) |
| "IgA nephropathy is associated with increased cardiovascular risk, though whether this is due to loss of kidney function or proteinuria is unclear." | ( Abdi-Ali, A; Ahmed, SB; Benediktsson, H; Hemmelgarn, BR; MacRae, JM; Mann, MC; Sola, DY; Turin, TC, 2015) |
| "HSP nephritis and IgA nephropathy are related diseases resulting from glomerular deposition of aberrantly glycosylated IgA1." | ( Coppo, R; Davin, JC, 2014) |
| "Immunoglobulin A nephropathy is defined by the presence of immunoglobulin A deposits in glomerular mesangial areas." | ( Hasegawa, K; Moniwa, N; Ogawa, Y; Shimamura, Y; Takizawa, H; Tsushima, T, 2014) |
| "IgA nephropathy is the most frequent type of glomerulonephritis worldwide." | ( Li, R; Liu, X; Tian, J; Wang, Y; Zhou, X, 2015) |
| "IgA nephropathy is the most common primary glomerular disease worldwide and also the most frequent cause of kidney failure." | ( Chen, Y; Li, Y; Liang, M; Yang, S, 2014) |
| "IgA nephropathy is the most common type of glomerulonephritis in the world." | ( Ding, J; Liu, X; Wang, D; Wang, F; Xiao, H; Zhong, X, 2015) |
| "IgA nephropathy is diagnosed by renal biopsy, an invasive procedure with a risk of significant complications." | ( Boron, J; Julian, BA; Kacer, P; Maixnerova, D; Neprasova, M; Novak, J; Novotny, P; Reily, C; Suchanek, M; Tesar, V, 2016) |
| "IgA nephropathy is not known to be a common pathological type." | ( Chen, YH; Li, HY; Li, PL; Li, SH; Liu, WW; Long, HB; Niu, HX, 2017) |
| "IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-20 years." | ( Barratt, J; Cook, H; Coppo, R; de Fijter, JW; Del Vecchio, L; Feehally, J; Fellström, BC; Floege, J; Hetzel, G; Jardine, AG; Locatelli, F; Maes, BD; Mercer, A; Ortiz, F; Praga, M; Sørensen, SS; Tesar, V, 2017) |
| "IgA nephropathy is the most common primary glomerulonephritis and one of the leading causes of end-stage renal disease." | ( Cao, L; Che, X; Fang, W; Gu, L; Min, L; Mou, S; Ni, Z; Qian, J; Wang, L; Wang, Q; Yu, Z; Yuan, J; Zhang, M; Zhou, W; Zhu, M, 2017) |
| "IgA nephropathy is an immune-mediated chronic glomerulonephritis with a great variability in clinical presentation and outcome." | ( Kovács, T; Máté, J; Nagy, J; Sági, B; Vas, T, 2017) |
| "IgA nephropathy is associated with aberrant O-glycosylation of IgA1, which is recognized by autoantibodies leading to the formation of circulating immune complexes." | ( Czernekova, L; Hill, M; Hruby, M; Jemelkova, J; Kafkova, LR; Kosztyu, P; Matousovic, K; Mestecky, J; Raska, M; Sterzl, I; Vondrak, K; Zadrazil, J, 2018) |
| "IgA nephropathy is one of the most common causes of renal hypertension." | ( Chen, H; Fan, L; Li, X; Tian, G; Wu, Y, 2018) |
| "IgA nephropathy is the most common type of primary glomerulonephritis worldwide." | ( McAdoo, S; Tam, FWK, 2018) |
| "Immunoglobulin A nephropathy is the most common primary glomerulonephritis worldwide, and it can be associated with liver disease." | ( Gocho, Y; Maeda, T; Ogawa, Y; Shimamura, Y; Takizawa, H; Tsuji, K, 2019) |
| "Immunoglobulin A nephropathy is a major cause of end-stage renal disease worldwide; previous methods of medical management, including use of renin-angiotensin system inhibitors and corticosteroids, remain unproven in clinical trials." | ( Hirano, K; Kawamura, T; Koike, K; Maruyama, S; Matsuo, S; Matsuzaki, K; Nishikawa, M; Suzuki, Y; Yasuda, T; Yasuda, Y; Yokoo, T, 2019) |
| "IgA nephropathy is the most common glomerulonephritis world-wide." | ( Craig, JC; Molony, DA; Natale, P; Palmer, SC; Ruospo, M; Saglimbene, VM; Samuels, JA; Schena, FP; Strippoli, GF; Vecchio, M, 2020) |
| "IgA nephropathy is the most common form of primary GN worldwide." | ( Berthier, CC; Gan, T; He, K; Hou, P; Hu, Y; Li, Y; Liu, LJ; Lv, JC; Patrick, MT; Qi, YY; Shi, SF; Tsoi, LC; Wang, YN; Xu, HJ; Zhang, H; Zhang, YM; Zhou, XJ, 2021) |
| "IgA nephropathy is virtually known as the most common glomerulopathy to end-stage renal failure in the world." | ( Deng, MH; Fu, R; Huang, YH; Peng, XJ; Tao, SS; Wang, TJ; Zheng, WM; Zhu, C, 2021) |
| "IgA nephropathy is caused by deposition of circulatory IgA1 in the kidney." | ( Gao, L; Jin, J; Liu, P; Lu, WH; Lv, J; Xie, X; Zhang, H, 2021) |
| "IgA nephropathy is the most common primary glomerular disease world-wide." | ( Ci, X; Du, X; Li, L; Lu, X; Luo, M; Wu, L; Xue, H, 2022) |
| "IgA nephropathy is the most common glomerular disease and is a common cause of progression to end-stage renal disease in patients with kidney diseases." | ( Chen, Q; Chen, Z; Guo, Y; Huo, Y; Li, H; Li, S; Liu, L; Lv, J; Shen, C; Sun, W; Wang, Z; Zhou, J, 2022) |
| "IgA nephropathy is the most common primary glomerulonephritis among adults in clinic." | ( Bi, J; Huang, Z; Li, Y; Li, Z; Liang, Y; Liu, L; Min, Q; Shao, M; Sun, H; Xu, H; Xu, Z; Yang, S; Yu, X; Zhang, L, 2023) |
| "IgA nephropathy is not uncommon for clinical practice." | ( Ji, M; Li, Z; Yang, Z, 2023) |
| "IgA nephropathy is the most common primary glomerulonephritis worldwide." | ( Maixnerova, D; Tesar, V, 2023) |
| Excerpt | Reference |
|---|
| "It was difficult for WM in treating IgA nephropathy, membrano-proliferative GN and focal glomerulosclerosis, but Chinese medicinal herbs were effective with replenishing Qi and strengthening the Spleen, clearing away Dampness-Heat, promoting blood circulation and relieving Stasis, etc." | ( Chen, YP; Hu, ZY; Zha, P, 1992) |
| "A single case of IgA nephropathy with a concomitant tubulointerstitial nephritis, developing during a long-term phenytoin therapy is reported." | ( Deák, G; Háber, A; Nagy, J; Süle, T, 1992) |
| "In an uncontrolled trial, patients with IgA nephropathy (IgAN) were treated with drugs that can alter the intestinal mucosal permeability to food antigens." | ( Arrigo, G; Bazzi, C; D'Amico, G; Petrini, C; Ragni, A; Rizza, V; Sinico, RA; Torpia, R, 1992) |
| "Twenty-nine patients with IgA nephropathy were normotensive and 20 hypertensive (diastolic pressure greater than or equal to 95 mm Hg or treated by antihypertensive drugs)." | ( Boero, R; Degli Esposti, E; Fabbri, A; Forneris, G; Fusaroli, M; Guarena, C; Piccoli, G; Quarello, F, 1991) |
| "In 3 out of 4 "positive" patients with IgA nephropathy, the levels of IgA antibody were suppressed after administration of SCG." | ( Kojima, H, 1991) |
| "In this study progressive IgA nephropathy was defined as follows; 24 hour urinary protein excretion was (++) or more and renal biopsy carried out just before the therapy revealed crescents, inevitably including cellular crescents, in 10% or more glomeruli observed." | ( Kida, H; Saito, Y; Sugioka, G; Takaeda, M; Yoshimura, M, 1991) |
| "Mesangial IgA nephropathy was experimentally induced in ddY mice by oral and parenteral administration of the poliomyelitis vaccine (POLIO), and we then tried to investigate if IgA deposition could be prevented by the concurrent use of sodium cromoglycate (SCG), which is known to inhibit the local mucosal immune reaction." | ( Choi, IJ; Jin, SY, 1990) |
| "Of 52 patients with mesangial IgA nephropathy, 25 were allocated to treatment with cyclophosphamide (6 months), and dipyridamole and warfarin (2 years) and 27 to no treatment in a randomized prospective 2-year study." | ( Kincaid-Smith, P; Owen, JE; Walker, RG; Yu, SH, 1990) |
| "We treated ten children with severe IgA nephropathy (IgAN) [proteinuria greater than 1 g/day, hypertension, renal insufficiency, segmental sclerosis, crescent formation and/or glomerular basement membrane (GBM) deposition of IgA] with prednisone and azathioprine for 1 year." | ( Andreoli, SP; Bergstein, JM, 1989) |
| "In patients with IgA nephropathy, treatment with fish oil for two years retards the rate at which renal function is lost." | ( Bergstralh, EJ; Donadio, JV; Holley, KE; Offord, KP; Spencer, DC, 1994) |
| "We describe a patient with immunoglobulin A nephropathy who was treated with sucrose-containing immunoglobulin." | ( Hansen-Schmidt, S; Keller, F; Silomon, J, 1996) |
| "We present a case of IgA nephropathy (IgAGN) which developed rapidly progressive glomerulonephritis and showed marked clinical improvement with treatment." | ( Kawakatsu, H; Mori, A; Nishida, M; Nomura, Y; Park, KI; Satoh, A; Yamazaki, Y, 1997) |
| "In this review, therapeutic trials for treatment of IgA nephropathy (Berger's disease) are reviewed and discussed." | ( Julian, BA; Nowack, R; Schiele, J; van der Woude, FJ, 1999) |
| "However, treatment of IgA nephropathy has not been well established." | ( Hayashi, T; Hori, M; Imai, E; Nakanishi, I; Okada, N; Shoji, T; Suzuki, A; Togawa, M; Tsubakihara, Y, 2000) |
| "Detection of genetic risk factors for IgA nephropathy will allow us to study further the pathogenesis of IgA nephropathy and devise effective therapy." | ( Iijima, K; Nakamura, H; Tanaka, R; Yoshikawa, N, 2000) |
| "Patients with immunoglobulin A nephropathy administered ACE inhibitors showed significantly lower renal TGF-beta1 gene expression than patients not administered these medications (mean ratios of TGF-beta1/beta-actin, 4." | ( Kim, D; Kim, HS; Kim, SJ; Ma, KA; Shin, GT, 2000) |
| "These data suggest that IgA nephropathy associated with severe inflammatory and crescenteric change can be effectively and safely treated with a low-cost regime based on oral corticosteroids and cyclophosphamide tailored to a plateau of treatment response in individual patients." | ( Fluck, RJ; Lambie, SH; McIntyre, CW, 2001) |
| "The binding ability of the lectin to untreated IgA1 from IgA nephropathy patients was significantly lower as compared to the untreated IgA1 from normal controls." | ( Chua, CT; Hashim, OH; Shuib, AS, 2001) |
| "Fish oil treatment in patients with IgA nephropathy, renal insufficiency and proteinuria did not affect the excretion of low- or high-molecular weight proteins, MCP-1 or TNF-alpha." | ( Branten, AJ; Klasen, IS; Wetzels, JF, 2002) |
| "For advanced progressive primary IgA nephropathy (IgAN) no established therapy exists." | ( Czock, D; Jehle, PM; Karges, W; Keller, F; Klotz, CH; Mertz, A; Muche, R; Rasche, FM, 2003) |
| "Steroid therapy for IgA nephropathy (IgAN) has been reported to ameliorate the long-term prognosis of IgAN, but its mode of action has not been fully elucidated." | ( Asahi, K; Asano, K; Eiro, M; Katoh, T; Kuriki, M; Sakurai, K; Suzuki, H; Watanabe, K; Watanabe, T, 2003) |
| "No satisfactory treatment exists for IgA nephropathy (IgAN), especially in patients with severe histologic damage." | ( Kanno, Y; Nakamoto, H; Nemoto, H; Okada, H; Sugahara, S; Suzuki, H; Witt, M, 2003) |
| "The availability of treatment for IgA nephropathy (IgAN) is limited." | ( Cai, G; Chen, X; Liu, H; Liu, S; Qiu, Q; Tang, L; Xie, Y, 2004) |
| "We report 3 patients with IgA nephropathy who were treated with mycophenolate mofetil for more than 1 year." | ( Bergner, R; Brass, H; Hoffmann, M; Uppenkamp, M, 2004) |
| "In 27 IgA nephropathy patients who received 2-year prednisolone treatment, we analyzed the differences in clinical and pathological parameters (1) between patients with and without disappearance of proteinuria (less than 0." | ( Fujigaki, Y; Hishida, A; Kimura, M; Ohura, M; Suzuki, T; Yamamoto, T; Yonemura, K, 2004) |
| "We present a patient with IgA nephropathy in whom continuous colchicine treatment induced remission, which has lasted for 22 years." | ( Blau, A; Kopolovic, J; Koukoui, L; Livneh, A; Pras, M, 2004) |
| "We report the first documented case of IgA nephropathy occurring after treatment of primary hyperparathyroidism." | ( Brandenburg, VM; Brodersen, HP; Janssen, U; Jochum, E, 2005) |
| "We enrolled 49 patients with IgA nephropathy (IgAN), treating some with ACE inhibitors (n = 26, 1-2 mg/day temocapril or trandolapril) and some with calcium-channel blockers (CCB, n = 23, 2." | ( Kanno, Y; Nakazato, Y; Okada, H; Suzuki, H; Yamaji, Y, 2005) |
| "We report a case of IgA nephropathy with tuberculous pleurisy that was treated with steroid pulse therapy combined with tonsillectomy." | ( Koike, K; Okuda, S; Sugawara, K; Takeda, K; Tamaki, K; Wakasugi, D, 2005) |
| "Sixty-two patients diagnosed as IgA nephropathy were randomly divided into control group and treatment group." | ( Guan, XD; Wu, YF; Zhao, W, 2005) |
| "The pathogenesis of IgA nephropathy is still unknown, and treatment remains controversial." | ( Agras, PI; Baskin, E; Bilezikci, B; Cengiz, N; Saatci, U, 2005) |
| "In animal models of IgA nephropathy, the inevitable endogenous immune response to passively administered antigens alone or in complex with specific IgA mask the exact role each might play in pathogenesis." | ( Chao, TK; Chen, A; Ka, SM; Kung, JT; Lee, WH; Lin, YF; Rifai, A; Shui, HA; Sytwu, HK; Yang, SM, 2006) |
| "Fourteen young patients with IgA nephropathy were evaluated for flow-mediated vasodilation (FMD), plasma levels of adiponectin both in high molecular weight (HMW adiponectin) form and in single molecular form (total adiponectin), hepatocyte growth factor (HGF), asymmetric dimethylarginine (ADMA), and high-sensitive C-reactive protein, before and after a course of GC pulse therapy." | ( Hanayama, Y; Kaihara, M; Maeshima, Y; Makino, H; Nakamura, Y; Norii, H; Sugiyama, H; Uchida, HA; Yamasaki, Y, 2006) |
| "Treatment options for progressive IgA nephropathy are limited." | ( Ashida, R; Furusu, A; Hiu, M; Horita, Y; Kohno, S; Tadokoro, M; Taguchi, T; Taura, K, 2007) |
| "Thirteen patients with refractory IgA nephropathy were treated with leflunomide and hormone therapy, and the clinical data were collected and evaluated before and in weeks 2, 4, 8, 12, 16, 20 and 24 during the treatment." | ( Liu, ZR; Rong, L, 2007) |
| "Twenty-four normotensive patients with IgA nephropathy were randomly assigned to receive olmesartan 10 mg/day, temocapril 2 mg/day, or combination therapy with both drugs." | ( Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Sugaya, T; Suzuki, T; Ueda, Y, 2007) |
| "(1) The hematuria in rats with IgA nephropathy significantly increased compared with normal control group and Astragalus treatment group (P < 0." | ( He, XJ; Mo, SH; Peng, XJ; Tan, H; Wu, XC; Yi, ZW; Zhang, GZ; Zheng, WM, 2008) |
| "10 patients (3 men) with biopsy-proven IgA nephropathy and persistent proteinuria despite angiotensin-converting enzyme-inhibitor or angiotensin receptor blocker therapy in a tertiary referral center." | ( Chow, KM; Chung, KY; Kwan, BC; Leung, CB; Li, PK; Szeto, CC, 2008) |
| "The benefits of steroid therapy in immunoglobulin A nephropathy (IgAN) have not been established." | ( Hirakata, H; Ikeda, K; Katafuchi, R; Kumagai, H; Mizumasa, T; Nagata, M; Ninomiya, T, 2008) |
| "Cyclosporine (CsA) treatment in immunoglobulin A nephropathy (IgAN) is controversial and has not been widely studied." | ( Hong, SW; Jeong, HJ; Kim, JH; Lim, BJ, 2009) |
| "Steroid was a main drug for treatment of IgA nephropathy." | ( Abe, Y; Hashimoto, K; Hosoya, M; Ito, M; Kawasaki, Y; Sakai, N; Suyama, K; Takano, K; Ushijima, Y, 2009) |
| "With regard to spontaneous IgA nephropathy, we investigated the effects of TJN-259 administered from 28 to 40 weeks." | ( Hasegawa, Y; Hattori, T; Inagaki, Y; Koseki, J; Sadakane, C; Shindo, S; Takeda, H; Takeda, S, 2009) |
| "In patients with IgA nephropathy, treatment with an ARB, valsartan (40 mg/day), significantly increased renal plasma flow and decreased filtration fraction, which were associated with reductions in urinary angiotensinogen levels." | ( Hamada, M; Hitomi, H; Imanishi, M; Kishida, M; Kobori, H; Konishi, Y; Maeda, I; Morikawa, T; Nishiyama, A; Ohashi, N; Shirahashi, N; Urushihara, M, 2011) |
| "The optimal treatment for IgA nephropathy (IgAN) remains unknown." | ( Allegri, L; Andrulli, S; Cirami, L; De Cristofaro, V; Del Vecchio, L; Fogazzi, G; Locatelli, F; Pani, A; Pozzi, C; Procaccini, AD; Scaini, P; Vogt, B, 2010) |
| "The treatment of adult IgA nephropathy with mizoribine alone, losartan alone or a combination of the 2 reduced 24 hours-UP." | ( Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011) |
| "Treatment of patients with IgA nephropathy with corticosteroids is followed by remission of proteinuria but still increased urinary IL-6 and TGF-β excretion." | ( Gerolymos, M; Goumenos, DS; Kalliakmani, P; Nakopoulou, L; Papasotiriou, M; Tsakas, S, 2011) |
| "For early IgA nephropathy patients with minimal proteinuria, normal blood pressure, and normal renal function, treatment with 2." | ( Chow, KM; Kwan, BC; Leung, CB; Li, PK; Szeto, CC, 2013) |
| "Treatment remains uncertain for IgA nephropathy patients with mild to moderate proteinuria, for whom anti-hypertensive medication or the RAS blocker is not applicable due to low blood pressure." | ( Chin, HJ; Kim, S; Kim, YC; Koo, HS, 2013) |
| "Patients with IgA nephropathy (n = 69) were recruited from five centres and randomly assigned to a treatment group (750 mg/day probucol plus 160 mg/day valsartan) or a control group (160 mg/day valsartan) and were followed for 3 years." | ( Feng, Z; Hou, S; Hu, H; Liang, Y; Shi, W; Shi, X; Wang, L; Wang, W; Xia, Y; Xu, L; Yan, H; Ye, Z; Zhang, B; Zhang, L; Zhong, W, 2014) |
| "Some patients with severe immunoglobulin A nephropathy (IgAN) are resistant to multi-drug combination therapy; however, there have been few reports on the risk factors for non-responsiveness to treatment for severe IgAN." | ( Hashimoto, K; Hosoya, M; Kanno, S; Kawasaki, Y; Miyazaki, K; Ono, A; Sato, M; Suyama, K; Suzuki, Y, 2014) |
| "We describe a patient with immunoglobulin A nephropathy who was diagnosed with progressive multifocal leukoencephalopathy (PML) and successfully treated with mefloquine, an antimalarial medication." | ( Byun, JI; Chu, K; Jung, KH; Lee, SK; Lee, ST; Lim, JA; Moon, J; Park, KI; Shin, JW, 2014) |
| "The current standard treatment for IgA nephropathy relies on steroid and/or immunosuppressive therapy and angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB)." | ( Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015) |
| "As a renal biopsy showed IgA nephropathy (IgAN), bilateral tonsillectomy was performed, and one course of steroid pulse therapy with an oral steroid and mizoribine were subsequently administered." | ( Fukui, M; Kaneko, T; Mii, A; Nagahama, K; Shimizu, A; Tsuruoka, S, 2015) |
| "We herein report 3 cases of progressive IgA nephropathy and their successful treatment with a combination of aspirin and eicosapentaenoic acid (EPA) without the use of steroids." | ( Arita, M; Hanafusa, N; Hayashi, M; Hirahashi, J; Hishikawa, K; Nangaku, M; Wada, T, 2015) |
| "No specific treatment for IgA nephropathy (IgAN) after kidney transplantation is currently available." | ( Ariaudo, C; Biancone, L; di Vico, MC; Fop, F; Mazzucco, G; Messina, M; Segoloni, GP, 2016) |
| "Because these findings indicated active IgA nephropathy, we decided to perform tonsillectomy and methylprednisolone pulse therapy." | ( Endo, M; Hasegawa, J; Honda, K; Kono, M; Ogawa, T; Shirakawa, H; Wakai, S, 2016) |
| "(3) The cause of IgA nephropathy with AKI: 13 patients had severe glomerular damage, including crescentic glomerulonephritis and diffuse endocapillary proliferation; 1 case was complicated with acute interstitial nephritis after being treated with antibiotics, 2 patients had decreased glomerular filtration rate because of taking benazepril or oral indomethacin, 1 case with renal tubular injury induced by gross hematuria, and the other two cases the reason was not clear." | ( Chen, MG; Liang, HY; Yang, Q; Ye, XH, 2016) |
| "Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive immunosuppressive therapy." | ( Chen, M; Cui, Z; Liu, L; Lv, J; Shi, S; Wang, X; Wang, Y; Xie, X; Yu, X; Zhang, H; Zhao, MH; Zhou, F; Zhu, L, 2016) |
| "Treatment of IgA nephropathy (IgAN) in Japan has recently changed, from oral prednisolone (oPSL) to tonsillectomy plus steroid pulse (TSP) therapy." | ( Hoshino, Y; Moriyama, T; Nitta, K; Tsuchiya, K; Uchida, K, 2017) |
| "We collected data for 44 IgA nephropathy children treated with multi-drug combination therapy." | ( Hosoya, M; Kawasaki, Y; Maeda, R; Ohara, S; Suyama, K, 2018) |
| "Treatment of IgA nephropathy using generalized immunosuppression is controversial, with concerns regarding the balance of safety and efficacy in a nonspecific approach." | ( McAdoo, S; Tam, FWK, 2018) |
| "After the establishment of IgA nephropathy model, rats were treated with different concentrations of rapamycin, and the protective effect of different concentrations of rapamycin on renal function of the rats was observed." | ( Bow, LM; Cui, X; Guo, N; Liu, S; Lu, S; Tian, J; Xu, S; Zhang, L, 2019) |
| "For retrospective cohort with IgA nephropathy, the patients who received corticosteroid therapy were recruited." | ( Li, R; Li, Y; Yang, H; Zhang, W, 2019) |
| "We herein report 2 patients with IgA nephropathy treated with lubiprostone (24 μg 1×/day)." | ( Nakamura, T; Node, K; Sato, E; Takeshita, M; Tanaka, A, 2019) |
| "The optimal therapy for immunoglobulin A nephropathy (IgAN) remains uncertain." | ( Feng, S; He, Z; Xu, S; Yi, J, 2019) |
| "In patients with IgA nephropathy and proteinuria > 1 g/day, steroid therapy given for generally two to four months with a tapering course probably prevents the progression to ESKD compared to placebo or standard care (8 studies; 741 participants: RR 0." | ( Craig, JC; Molony, DA; Natale, P; Palmer, SC; Ruospo, M; Saglimbene, VM; Samuels, JA; Schena, FP; Strippoli, GF; Vecchio, M, 2020) |
| "The use of immunosuppressive therapy for IgA nephropathy patients with renal insufficiency and severe proteinuria is controversial." | ( Bai, M; Dong, R; Li, L; Li, R; Liu, C; Ma, F; Sun, S; Yang, X; Zhao, L; Zhou, M, 2020) |
| "We report here the onset of a severe IgA nephropathy requiring hemodialysis which occurred several weeks after trifluridine/tipiracil treatment." | ( Brochériou, I; Desbuissons, G; Fournier, P; Ngango, L, 2020) |
| "The specific treatment regimens of IgA nephropathy (IgAN) patients with moderate proteinuria (1." | ( Pei, G; Qin, W; Tan, J; Tan, L; Tang, Y; Zhong, Z, 2021) |
| "There is no a unified opinion in the treatment of IgA nephropathy." | ( Huang, T; Liu, X; Wang, J; Wang, L; Xu, G; Yan, Z, 2022) |
| "Among patients with IgA nephropathy at high risk of progression, treatment with oral methylprednisolone for 6 to 9 months, compared with placebo, significantly reduced the risk of the composite outcome of kidney function decline, kidney failure, or death due to kidney disease." | ( Agarwal, R; Barbour, S; Billot, L; Cass, A; Cattran, D; Chan, TM; Feehally, J; Floege, J; Glassock, R; Hladunewich, MA; Hooi, LS; Jardine, MJ; Jha, V; Johnson, DW; Levin, A; Liu, ZH; Lv, J; Monaghan, H; Perkovic, V; Reich, HN; Remuzzi, G; Rogers, K; Stepien, S; Wheeler, DC; Wong, MG; Woodward, M; Wu, Y; Zhang, H; Zhao, M, 2022) |
| "The Oxford classification of IgA nephropathy (MEST-C score) suggested more inflammatory activity in the immunosuppressive therapy group, including more crescents and endocapillary hypercellularity." | ( Beck, N; Schneider, J; Walz, G, 2022) |
| "Clinical evidence supporting artesunate treatment of IgA nephropathy is currently lacking, and we expect that the results of this trial will provide high-quality clinical evidence for artesunate as a treatment option for IgA nephropathy in the future." | ( Chen, Q; Chen, Z; Guo, Y; Huo, Y; Li, H; Li, S; Liu, L; Lv, J; Shen, C; Sun, W; Wang, Z; Zhou, J, 2022) |
| "Steroids (60 mg/d) were used to treat IgA nephropathy daily." | ( Hao, W; Jia, Y; Wang, H; Wang, X; Xu, H; Yu, J, 2022) |
| "We diagnosed highly active IgA nephropathy and initiated treatment with prednisolone and azathioprine." | ( Hattori, K; Ishikawa, R; Shimizu, R; Tamai, H; Tanaka, S; Terashima, T; Watanabe, T; Yamazaki, M, 2023) |
| "We diagnosed highly active IgA nephropathy and initiated treatment with prednisolone and azathioprine." | ( Hattori, K; Ishikawa, R; Shimizu, R; Tamai, H; Tanaka, S; Terashima, T; Watanabe, T; Yamazaki, M, 2023) |
| "The use of corticosteroids to treat IgA nephropathy (IgAN) has been limited by many controversies related to uncertain benefit and safety concerns." | ( Barbour, SJ; Barratt, J; Ghaddar, M, 2023) |
| "Approximately 20-40% of IgA nephropathy patients would develop end-stage renal disease, for whom safety concerns remained a major setback when using conventional pharmaceutical treatments." | ( Du, W; Fan, L; Ni, X; Tan, Q; Xue, H, 2023) |
| "This retrospective study involved 30 immunoglobulin A nephropathy patients with active histological lesions, 15 of whom were treated with both mycophenolate mofetil 2 g/day for 6 months and 3 pulses of 15 mg/kg methylprednisolone, followed by a short tapering schedule of oral prednisone." | ( Careddu, A; Fenoglio, R; Ferro, M; Naretto, C; Quattrocchio, G; Roccatello, D; Sciascia, S, 2023) |
| "There is no standard recommendation for IgA nephropathy treatment in children." | ( Mao, Y; Shen, J; Yin, L; Zhang, C; Zhou, W; Zhou, Z, 2023) |
| "We suggest proactive immunosuppressive treatment in IgA nephropathy in children." | ( Mao, Y; Shen, J; Yin, L; Zhang, C; Zhou, W; Zhou, Z, 2023) |